VRDN: Koefisien rega marang pendapatan Viridian Pharma

The development of innovative antibodies to combat TED serves as the primary growth driver for Viridian Therapeutics (VRDN). The establishment of an advanced scientific hub for thyroid therapy validates this strategy through the current P/S valuation, where the 132.80 level reflects the state of the price-to-sales capitalization parameter. Currently, the business relies on independent R&D and proprietary clinical trials without external mergers.

VRDN: Multiplikator P/S Viridian Therapeutics, Inc. 04.07.2022 - 14.11.2026

Rincian analitis perusahaan Viridian Pharma (VRDN)

- rega saiki lan proyeksi nilai saham:

Bagan rega viridiantherapeutics.com|VRDN - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar Viridian Pharma|VRDN - Nilai Total Perusahaan

- rincian nilai buku perusahaan:

Nilai Akuntansi Saham Viridian Therapeutics|VRDN - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku viridiantherapeutics.com|VRDN - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Rasio Utang marang Ekuitas Viridian Therapeutics|VRDN - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Viridian Corp|VRDN - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Viridian Pharma|VRDN - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Viridian Therapeutics|Rasio jangkoan perantara viridiantherapeutics.com

- informasi bathi lan kelipatan valuasi:

VRDN - Penghasilan resik|Bathi resik mangsa ngarep Viridian Therapeutics|VRDN - Pangali P/E|Pangali mangsa ngarep rega marang bathi Viridian Therapeutics Inc|VRDN - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Viridian Pharma|VRDN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Viridian Therapeutics|VRDN - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan viridiantherapeutics.com|VRDN - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Viridian Therapeutics

- rincian pendapatan lan dodolan emiten:

VRDN - Pendapatan lan volume dodolan|Volume dodolan sing dikarepake perusahaan viridiantherapeutics.com|VRDN - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Viridian Pharma

Analisis umum perusahaan:VRDN viridiantherapeutics.com

Produk sing diprodhuksi Viridian Therapeutics

For Viridian Therapeutics (VRDN), which invests in advanced R&D for ophthalmological drugs, the P/S multiple serves as an indicator of market expectations regarding the future commercialization of innovations. By analyzing the revenue multiple trend, an investor correlates the current market value of the business with the volume of generated sales, allowing for the timely identification of the risk of overpaying for the asset should product implementation rates stagnate.

Pesaing Viridian Therapeutics

Rasio rega marang pendapatan ALC (alcon.com)|Multiplikator P/S BLCO (Bausch + Lomb)|Koefisien rega marang pendapatan Glaukos Corp (GKOS)|APLS - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan BLTE (Belite Bio, Inc)|OCUL: Multiplikator P/S|HROW - Koefisien rega marang pendapatan|LENZ (LENZ Therapeutics) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan OCS (Oculis Holding)|Multiplikator P/S EYPT|Koefisien rega marang pendapatan Kodiak Corp|Multiplikator P/S ALDX (Aldeyra Therapeutics, Inc.)|Multiplikator P/S KALA BIO Inc. KALA|IRD - Rasio rega marang pendapatan|OKYO (OKYO Pharma Limited) - Rasio kapitalisasi marang pendapatan|ADVM (adverum.com) - Kapitalisasi marang pendapatan|Outlook Therapeutics Corp - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CLSD|NBY (NovaBay) - Kapitalisasi marang volume dodolan|Multiplikator P/S KPRX|ALIM (alimerasciences.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EYEN (Eyenovia)|Guardion Health (GHSI) - Rega marang dodolan|OCUP - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OPT (opthea.com)